IGC Pharma (IGC) Fundamental Analysis: Revenue, Earnings & Valuation

5.31 / 10

Netural

Fundamental assessment scores 5.3/10, indicating moderate health. Strengths include inventory turnover, accounts receivable turnover and asset efficiency; weaknesses are a negative revenue YoY growth and high income‑tax‑to‑profit ratio. Overall outlook is neutral.

Analysis Checks(8/10)

Revenue-MV

Value-0.28

Score3/3

Weight35.83%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value-5.50

Score1/3

Weight-4.36%

1M Return-1.40%

Inventory turnover ratio

Value0.45

Score2/3

Weight-2.26%

1M Return-0.66%

Accounts receivable turnover ratio

Value34.82

Score2/3

Weight-2.01%

1M Return-0.65%

PB-ROE

Value2.35

Score2/3

Weight40.17%

1M Return8.98%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-4.58%

1M Return-1.54%

Fixed assets turnover ratio

Value0.37

Score2/3

Weight-3.21%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.27%

1M Return-0.73%

Cost of sales ratio (%)

Value51.30

Score2/3

Weight-2.23%

1M Return-0.74%

Asset-MV

Value-0.48

Score2/3

Weight44.94%

1M Return9.91%

Is IGC undervalued or overvalued?

IGC scores 5.31/10 on fundamentals and holds a Fair valuation at present. Backed by its -47.43% ROE, -582.82% net margin, -4.02 P/E ratio, 3.20 P/B ratio, and 65.00% earnings growth, these metrics solidify its Netural investment rating.